60.67
-2.39 (-3.79%)
| Penutupan Terdahulu | 63.06 |
| Buka | 62.30 |
| Jumlah Dagangan | 174,145 |
| Purata Dagangan (3B) | 279,061 |
| Modal Pasaran | 1,805,399,552 |
| Harga / Buku (P/B) | 4.11 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2024 |
| EPS Cair (TTM) | -3.95 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.38% |
| Nisbah Semasa (MRQ) | 19.36 |
| Aliran Tunai Operasi (OCF TTM) | -84.15 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -54.26 M |
| Pulangan Atas Aset (ROA TTM) | -17.91% |
| Pulangan Atas Ekuiti (ROE TTM) | -25.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Disc Medicine, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -3.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.13 |
|
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 12.48% |
| % Dimiliki oleh Institusi | 97.80% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 118.00 (HC Wainwright & Co., 94.50%) | Beli |
| Median | 89.00 (46.70%) | |
| Rendah | 70.00 (Scotiabank, 15.38%) | Beli |
| Purata | 90.40 (49.00%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 58.31 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Stifel | 10 Dec 2024 | 90.00 (48.34%) | Beli | 67.47 |
| HC Wainwright & Co. | 09 Dec 2024 | 118.00 (94.49%) | Beli | 64.66 |
| 13 Nov 2024 | 118.00 (94.49%) | Beli | 63.06 | |
| Scotiabank | 05 Nov 2024 | 70.00 (15.38%) | Beli | 64.78 |
| 16 Oct 2024 | 62.00 (2.19%) | Beli | 47.99 | |
| Jefferies | 23 Oct 2024 | 89.00 (46.70%) | Beli | 46.99 |
| Cantor Fitzgerald | 15 Oct 2024 | 85.00 (40.10%) | Beli | 47.64 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |